Vacis has developed a platform technology to provide autologous soft tissue solutions to patients. The goal is to improve patients' lives by offering an autologous alternative to currently available artificial solutions. The applications range from vascular access to urology. Interest has also been shown in the field of reconstructive breast surgery. After long and extensive preclinical research, Vacis has successfully concluded their clinical study and is on the pathway to CE certification within the EU. Vacis is providing solutions of the highest quality, which was confirmed by our ISO 13485 certification in 2020.
